학술논문
744MO AdvanTIG-202: Phase II randomized, multicenter, open-label study of tislelizumab (TIS) with or without ociperlimab (OCI) in patients (pts) with previously treated recurrent/metastatic (R/M) cervical cancer (CC)
Document Type
Abstract
Author
Source
In Annals of Oncology October 2023 34 Supplement 2:S509-S510
Subject
Language
ISSN
0923-7534